title: Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America.
abstract: Annual trivalent influenza vaccines (TIV) containing 2 A strains and one B lineage have been recommended for the prevention of influenza in most of Latin American countries. However, the circulation of 2 B lineages (Victoria and Yamagata) and difficulties in predicting the predominating lineage have led to the development of quadrivalent influenza vaccines (QIV), including both B lineages. Thus, the objective was to estimate the public health impact and influenza-related costs if QIV would have been used instead of TIV in 3 Latin American countries. We used a static model over the seasons 2010-2014 in Brazil, 2007-2014 in Colombia and 2006-2014 in Panama, focusing on population groups targeted by local vaccination recommendations: young children, adults with risk factors and the elderly. In Brazil, between 2010 and 2014, using QIV instead of TIV would have avoided US$ 6,200 per 100,000 person-years in societal costs, based on 168 influenza cases, 89 consultations, 3.2 hospitalizations and 0.38 deaths per 100,000 person-years. In Colombia and Panama, these would have ranged from US$ 1,000 to 12,700 (based on 34 cases, 13-25 consultations, 0.6-8.9 hospitalizations and 0.04-1.74 deaths) and from US$ 3,000 to 33,700 (based on 113 cases, 55-82 consultations, 0.5-27.8 hospitalizations and 0.08-6.87 deaths) per 100,000 person-years, respectively. Overall, the broader protection offered by QIV would have reduced the influenza humanistic and economic burden in the 3 countries. Despite the lack of local data leading to several extrapolations, this study is the first to give quantitative estimates of the potential benefits of QIV in Latin America.
authors.affiliation: a Creativ-Ceutical , Paris , France.
authors.forename: Aurélien
authors.initials: A
authors.lastname: Jamotte
authors.affiliation: a Creativ-Ceutical , Paris , France.
authors.forename: Emilie
authors.initials: E
authors.lastname: Clay
authors.affiliation: b Sanofi Pasteur , Lyon , France.
authors.forename: Bérengère
authors.initials: B
authors.lastname: Macabeo
authors.affiliation: c Sanofi Pasteur , Bogota , Colombia.
authors.forename: Andrès
authors.initials: A
authors.lastname: Caicedo
authors.affiliation: d Sanofi Pasteur , Mexico , Mexico.
authors.forename: Juan Guillermo
authors.initials: JG
authors.lastname: Lopez
authors.affiliation: e Sanofi Pasteur Latin America , Sao Paulo , Brazil.
authors.forename: Lucia
authors.initials: L
authors.lastname: Bricks
authors.affiliation: f Salutia Foundation , Bogota , Colombia.
authors.forename: Martín
authors.initials: M
authors.lastname: Romero Prada
authors.affiliation: f Salutia Foundation , Bogota , Colombia.
authors.forename: Rubén
authors.initials: R
authors.lastname: Marrugo
authors.affiliation: f Salutia Foundation , Bogota , Colombia.
authors.forename: Pamela
authors.initials: P
authors.lastname: Alfonso
authors.affiliation: g The Gorgas Memorial Institute for Health Studies , Panama City , Panama.
authors.forename: Brechla
authors.initials: B
authors.lastname: Moreno Arévalo
authors.affiliation: g The Gorgas Memorial Institute for Health Studies , Panama City , Panama.
authors.forename: Danilo
authors.initials: D
authors.lastname: Franco
authors.affiliation: h Ministry of Health , Panama City , Panama.
authors.forename: Lourdes
authors.initials: L
authors.lastname: Garcia Diaz
authors.affiliation: h Ministry of Health , Panama City , Panama.
authors.forename: Yadira
authors.initials: Y
authors.lastname: Isaza de Molto
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001938:Brazil / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D003105:Colombia / Q000453:epidemiology; D017048:Health Care Costs; D006801:Humans; D007223:Infant; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000191:economics / Q000276:immunology*; D007251:Influenza, Human / Q000191:economics / Q000453:epidemiology* / Q000517:prevention & control*; D008875:Middle Aged; D010176:Panama / Q000453:epidemiology; D055815:Young Adult
chemical_list: D007252:Influenza Vaccines
keywords: Brazil; Colombia; Latin America; Panama; benefit; cost; influenza; public health; quadrivalent; vaccine